

METALLOTHERAPEUTIC DRUGS AND METAL-BASED DIAGNOSTIC AGENTS

THE USE OF METALS IN MEDICINE

**Marcel Gielen
Edward R.T. Tiekink**



John Wiley & Sons, Ltd

METALLOTHERAPEUTIC DRUGS AND METAL-BASED DIAGNOSTIC AGENTS

METALLOTHERAPEUTIC DRUGS AND METAL-BASED DIAGNOSTIC AGENTS

THE USE OF METALS IN MEDICINE

**Marcel Gielen
Edward R.T. Tiekink**



John Wiley & Sons, Ltd

Copyright © 2005 John Wiley & Sons Ltd, The Atrium, Southern Gate, Chichester,
West Sussex PO19 8SQ, England

Telephone (+44) 1243 779777

Email (for orders and customer service enquiries): cs-books@wiley.co.uk
Visit our Home Page on www.wiley.com

All Rights Reserved. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, scanning or otherwise, except under the terms of the Copyright, Designs and Patents Act 1988 or under the terms of a licence issued by the Copyright Licensing Agency Ltd, 90 Tottenham Court Road, London W1T 4LP, UK, without the permission in writing of the Publisher. Requests to the Publisher should be addressed to the Permissions Department, John Wiley & Sons Ltd, The Atrium, Southern Gate, Chichester, West Sussex PO19 8SQ, England, or emailed to permreq@wiley.co.uk, or faxed to (+44) 1243 770620.

Designations used by companies to distinguish their products are often claimed as trademarks. All brand names and product names used in this book are trade names, service marks, trademarks or registered trademarks of their respective owners. The Publisher is not associated with any product or vendor mentioned in this book.

This publication is designed to provide accurate and authoritative information in regard to the subject matter covered. It is sold on the understanding that the Publisher is not engaged in rendering professional services. If professional advice or other expert assistance is required, the services of a competent professional should be sought.

Other Wiley Editorial Offices

John Wiley & Sons Inc., 111 River Street, Hoboken, NJ 07030, USA

Jossey-Bass, 989 Market Street, San Francisco, CA 94103-1741, USA

Wiley-VCH Verlag GmbH, Boschstr. 12, D-69469 Weinheim, Germany

John Wiley & Sons Australia Ltd, 33 Park Road, Milton, Queensland 4064, Australia

John Wiley & Sons (Asia) Pte Ltd, 2 Clementi Loop #02-01, Jin Xing Distripark, Singapore 129809

John Wiley & Sons Canada Ltd, 22 Worcester Road, Etobicoke, Ontario, Canada M9W 1L1

Wiley also publishes its books in a variety of electronic formats. Some content that appears in print may not be available in electronic books.

Library of Congress Cataloging in Publication Data

Tiekink, Edward R.

Metallotherapeutic drugs and metal-based diagnostic agents – the use of
metals in medicine / Edward R. Tiekink & Marcel Gielen.

p. cm.

Includes index.

ISBN 0-470-86403-6

1. Metals—Therapeutic use. 2. Metals—Diagnostic use. I. Gielen, M.
(Marcel), 1938– II. Title.

RM666.M513T546 2005

615'.23—dc22

2004022079

British Library Cataloguing in Publication Data

A catalogue record for this book is available from the British Library

ISBN 0-470-86403-6

Typeset in 10/12pt Times by Integra Software Services Pvt. Ltd, Pondicherry, India

Printed and bound in Great Britain by TJ International, Padstow, Cornwall

This book is printed on acid-free paper responsibly manufactured from sustainable forestry in which at least two trees are planted for each one used for paper production.

Contents

List of Contributors	xxvi
Preface	xxxvii
1 ³Li Lithium Metallotherapeutics	1
<i>Robin S.B. Williams and Adrian J. Harwood</i>	
1.1 Introduction	1
1.2 The Inorganic Chemistry of Lithium	2
1.3 Biology of Lithium	3
1.3.1 The history of lithium therapeutics	3
1.3.2 Lithium and the body	4
1.4 Targets of Lithium	5
1.4.1 Glycogen synthase kinase-3	5
1.4.2 Inositol phosphate signalling	8
1.5 Lithium Therapeutics	10
1.5.1 Bipolar disorder and schizophrenia	10
1.5.2 Alzheimer's disease	12
1.5.3 Ischemia (stroke)	14
1.5.4 Adverse effects	14
Acknowledgements	15
References	15

2	^{5}B Boron Compounds as Therapeutic Drugs	19
	<i>Geeta Rana, Kamesh Vyakaranam, John A. Maguire and Narayan S. Hosmane</i>	
2.1	Boron Neutron Capture Therapy	19
2.2	Classes of Boron Compounds for Potential Use in BNCT	22
	2.2.1 DNA binders	22
	2.2.2 Boron-containing amino acids and related peptides	24
	2.2.3 Boron-containing nucleic acid precursors	27
2.3	Phosphates, Phosphonates and Phosphoramidates	31
2.4	Amines	33
2.5	Boron Analogues of Pyrophosphates	33
2.6	Boronated Polyamines	34
2.7	Carbohydrates	36
2.8	Lipoproteins	36
2.9	Lipids and Phospholipids	37
2.10	Radiation Sensitizers	38
2.11	Cyclic Thiourea Derivatives	38
2.12	Central Nervous System (CNS) Depressants: Promazines, Hydantoins and Barbiturates	39
2.13	Hydantoins and Barbiturates	39
2.14	Oligonucleotide Antisense Agents	40
2.15	Hormones	42
2.16	Liposomes	44

2.17	Conclusions	45
	Acknowledgements	46
	References	46
3	¹²Mg The Role of Magnesium as a Metallotherapeutic Drug	51
	<i>Pietro Delva</i>	
3.1	Introduction	51
3.2	Magnesium as a Drug	53
	3.2.1 Gestational hypertension, preeclampsia and eclampsia	53
	3.2.2 Asthma	54
	3.2.3 Stroke	55
	3.2.4 Acute myocardial infarction	57
	3.2.5 Arrhythmias	60
	3.2.6 Miscellaneous	61
	References	62
4	¹³Al Aluminum Metallotherapeutics	65
	<i>Thanos Salifoglou</i>	
4.1	Introduction	65
4.2	Adjuvants	66
	4.2.1 Alum	66
	4.2.2 Al(OH) ₃	67
	4.2.3 Aluminum phosphate	69
4.3	Antacids	69
	4.3.1 Aluminum hydroxide	69
	4.3.2 Aluminum glycinate	70
	4.3.3 Peptic ulcer disease	70
	4.3.4 Bismuth aluminum carbonate	73
	4.3.5 Bismuth–magnesium–sodium alumino-silicate	73
4.4	Phosphate Binders	73
	4.4.1 Basic aluminum carbonate	75
	4.4.2 Alumino-silicates	75

4.5	Alginate Raft Formulations	75
4.6	Blistering Diseases in the Elderly	77
4.7	Metabolic Diseases and Aluminum	77
4.8	Anti-malarial Substances	78
4.9	Potential Aluminum Toxicity	79
4.10	Conclusions	80
	References	80
5	¹⁴Si Biological Activity of Organosilicon Compounds	83
	<i>Edmunds Lukevics and Luba Ignatovich</i>	
5.1	Introduction	83
5.2	Organosilicon Modification	84
	5.2.1 O-, S- and N-Silylation	84
	5.2.2 C-Silylation	89
5.3	Sila Analogues	92
5.4	Specific Organosilicon Compounds	94
	References	96
6	²⁰Ca The Role of Calcium as a Metallotherapeutic Drug	109
	<i>Mario Barbagallo and Ligia J. Dominguez</i>	
6.1	Introduction	109
6.2	Calcium Homeostasis	110
6.3	Hormonal Regulation of Calcium Metabolism	111
6.4	Optimal Amount of Dietary Calcium Intake and Benefits of Calcium Supplementation	112

6.5	Osteoporosis	115
6.6	Hypertension	116
6.7	Hypertension in Pregnancy and Preeclampsia	118
6.8	Colon Cancer	119
6.9	Weight Control and Regulation of Body Fat	119
6.10	Periodontal Disease	120
6.11	Kidney Stones	121
6.12	Calcium Supplements: Side Effects	121
6.13	Conclusions	122
	References	123
7	²²Ti Anti-tumor Titanium Drugs	125
	<i>Erich Dubler</i>	
7.1	Introduction	125
7.2	The Biochemistry of Titanium	126
7.3	Titanium Anti-cancer Drugs	127
7.4	Budotitane	130
	7.4.1 Chemistry and anti-cancer activity	130
	7.4.2 Isomer abundance of budotitane	131
	7.4.3 Reaction with biomolecules	133
	7.4.4 Animal studies	134
	7.4.5 Clinical investigations	134
7.5	Titanocene Dichloride	135
	7.5.1 Chemistry and anti-cancer activity	135
	7.5.2 Reaction with biomolecules	136
	7.5.3 Animal studies	137
	7.5.4 Clinical investigations	138
	7.5.5 Perspectives of titanocene dichloride	138

7.6	Conclusions	139
	Acknowledgements	140
	References	140
8	²³V Insulin-Mimetic Vanadium-Containing Compounds	143
	<i>Tamás Kiss and Tamás Jakusch</i>	
8.1	Chemistry of Vanadium	143
8.2	Biological and Medicinal Aspects of Vanadium	144
8.3	The Role of Insulin in Glucose Metabolism	144
8.4	Vanadium Complexes with Biological Activity	145
8.5	Biological Activity and Toxicity of Various Vanadium(IV/V) Compounds	148
8.6	Speciation of VI(IV) Complexes in Biological Fluids	149
8.7	Possible Mechanism for <i>in vivo</i> Vanadium Action	153
8.8	Conclusion	155
	Acknowledgements	156
	References	156
9	²⁵Mn Manganese Metallotherapeutics	159
	<i>Jeanne H. Freeland-Graves, Tanushree Bose and Abbass Karbassian</i>	
9.1	Prevalence in the Environment	159
9.2	Diet and Water	160
9.3	Functions	160

9.4	MnSOD	160
9.5	Deficiency	161
	9.5.1 Animals	161
	9.5.2 Humans	162
9.6	Toxicity	162
9.7	Therapeutic Manganese-Related Agents	163
9.8	Therapeutic Uses	165
	9.8.1 Arthritis	165
	9.8.2 Cancer	166
	9.8.3 Cardiovascular diseases	167
	9.8.4 Dermatitis	168
	9.8.5 Diabetes	168
	9.8.6 Epilepsy	169
	9.8.7 Human immunodeficiency virus	169
	9.8.8 Inflammatory pain and response	170
	9.8.9 Ischemia and reperfusion injury	171
	9.8.10 Osteoporosis	171
	9.8.11 Peritoneal adhesions	172
	9.8.12 Premenstrual syndrome	172
	9.8.13 Shortened life span (premature aging)	173
	9.8.14 Other disorders	174
9.9	Magnetic Resonance Imaging (MRI)	174
9.10	Future Implications	175
	Acknowledgements	175
	References	176
10	²⁶Fe The Use of Iron-Based Drugs in Medicine	179
	<i>Xiang Wu and Mei Lin Go</i>	
10.1	Introduction	179
10.2	Ferrocene	180

10.3	TMH Ferrocene	181
10.4	Ferrocene in Drug Design	181
10.4.1	Examples where introduction of ferrocene has resulted in a loss or no change in activity	182
10.4.2	Examples where introduction of ferrocene has resulted in enhanced activity or a change in activity profile	183
10.5	Ferrochloroquine	185
10.6	Other Ferrocenyl Anti-plasmodial Agents	191
10.7	Organoiron as Anti-cancer Agents	193
10.8	Conclusions	197
	References	198
11	²⁷Co Cobalt Complexes as Potential Pharmaceutical Agents	201
	<i>Hui Chao and Liang-Nian Ji</i>	
11.1	Introduction	201
11.2	Enzyme Inhibition/Induction	202
11.2.1	Serine protease inhibitors	202
11.2.2	Topoisomerase II inhibitors	202
11.2.3	Heme oxygenase-1 inducers	203
11.3	Nucleic Acid Binding and Cleavage	204
11.3.1	Cobalt(III) polypyridyl complexes	204
11.3.2	Cobalt(III) bleomycin complexes	206
11.3.3	Cobalt(III) polyamine complexes	208
11.4	Miscellaneous	209
11.4.1	Cobalamin conjugates as drug delivery devices	209
11.4.2	Hypoxic selective agents	211
11.4.3	PET imaging agents	213
11.5	Conclusions	214

	Acknowledgements	214
	References	214
12	²⁹Cu Chemotherapeutic Copper Compounds	219
	<i>Francisco González-Vílchez and Rosario Vilaplana</i>	
12.1	Introduction	219
12.2	Copper-Purine Derivatives Complexes	220
12.3	Copper-Thiosemicarbazone Complexes	223
12.4	Copper-Benzohydroxamic Acid Complexes	230
12.5	Copper-Imidazole Derivatives Complexes	230
12.6	Copper-Polycarboxylate Complexes	233
	Acknowledgements	234
	References	235
13	³⁰Zn The Role of Zinc as a Metallotherapeutic Agent	237
	<i>Jane V. Higdon and Emily Ho</i>	
13.1	Introduction	237
13.2	Functions	237
	13.2.1 Catalytic functions	238
	13.2.2 Structural functions	238
	13.2.3 Regulatory functions	238
13.3	Zinc Deficiency	238
	13.3.1 Severe zinc deficiency	239
	13.3.2 Mild zinc deficiency	239
	13.3.3 Growth retardation	239

13.4	Increased Susceptibility to Infectious Disease	240
13.4.1	Diarrhea	240
13.4.2	Pneumonia	240
13.4.3	Malaria	240
13.5	Risk Factors for Zinc Deficiency	241
13.5.1	Dietary factors that decrease zinc absorption	241
13.5.2	Intake recommendations	241
13.6	Therapeutic Uses of Zinc	243
13.6.1	Wilson disease	243
13.6.2	Age-related macular degeneration	243
13.6.3	Human immunodeficiency virus (HIV) infection	243
13.6.4	Type 1 diabetes	244
13.6.5	Wound healing	244
13.7	Common Cold	245
13.7.1	Oral zinc	245
13.7.2	Intranasal zinc	245
13.8	Zinc Status and Its Relevance to Cancer	245
13.8.1	Zinc deficiency and oxidative stress	246
13.8.2	Zinc and DNA repair	247
13.8.3	Zinc and prostate cancer	249
13.9	Safety	251
13.9.1	Toxicity	251
13.9.2	Drug interactions	252
13.10	Conclusions	252
	References	252
14	³¹Ga Therapeutic Gallium Compounds	259
	<i>Lawrence R. Bernstein</i>	
14.1	Introduction	259
14.2	Chemistry and Mechanisms of Action	260
14.2.1	Aqueous biochemistry	260

14.2.2	Gallium and iron	261
14.2.3	Mechanisms of action	264
14.3	Therapeutic Gallium Compounds	265
14.3.1	Gallium nitrate and citrated gallium nitrate	265
14.3.2	Gallium chloride	269
14.3.3	Gallium 8-quinolinolate	269
14.3.4	Gallium maltolate	270
14.3.5	Other gallium compounds	271
	Abbreviations Used	273
	References	273
15	³²Ge Biological Activity of Organogermanium Compounds	279
	<i>Edmunds Lukevics and Luba Ignatovich</i>	
15.1	Introduction	279
15.2	Biological Activity	282
15.2.1	2-Carboxyethylgermanium sesquioxide	282
15.2.2	Spirogermanium	285
15.2.3	Germatranes	286
15.2.4	Germanium modified organic compounds	288
	References	290
16	³³As Metallotherapeutic Arsenic Compounds	297
	<i>Paul C. Ho</i>	
16.1	Introduction	297
16.2	Chemistry of Arsenic	299
16.3	Mechanisms of Action	300
16.3.1	Modulation of PML and PML–RAR α genes	301
16.3.2	Induction of intracellular reactive oxygen species (ROS)	302
16.3.3	Collapse of the mitochondrial membrane potential	303

16.3.4	Roles of glutathione	303
16.3.5	Down-regulation of bcl-2	304
16.3.6	Involvement of p53	304
16.3.7	Activation of caspases	305
16.3.8	Other mechanisms of arsenic-induced apoptosis	305
16.4	Pharmacokinetic Profiles	306
16.4.1	Absorption, distribution and excretion	306
16.4.2	Metabolism	306
16.5	Toxic Side Effects of As₂O₃	307
16.6	Indications and Uses of As₂O₃	308
16.7	Summary and Conclusions	308
	Acknowledgements	309
	References	309
17	³⁴Se The Use of Selenium-Based Drugs in Medicine	313
	<i>Michael Carland and Tahli Fenner</i>	
17.1	Introduction to Selenium and its Biochemistry	313
17.2	Diseases Associated with Selenium Deficiency	315
17.2.1	Asthma	316
17.2.2	Keshan disease	316
17.2.3	Human immunodeficiency virus (HIV)	317
17.3	Therapeutic Uses of Supranutritional Doses of Selenium	317
17.3.1	Arsenism	317
17.3.2	Cancer prevention	318
17.4	Synthetic Selenium-Containing Therapeutics	321
17.4.1	Anti-oxidants and anti-inflammatory agents	321
17.4.2	Anti-cancer	324
17.4.3	Anti-hypertensives	327
17.4.4	Anti-virals and anti-bacterials	327

17.5	Conclusion	328
	References	328
18	⁴³Tc Technetium in Medicine	333
	<i>Oyebola O. Sogbein and John F. Valliant</i>	
18.1	Overview	333
18.2	Technetium: Historical Accounts and Properties Relevant to Nuclear Medicine	334
18.3	Technetium Radiopharmaceuticals	336
	18.3.1 Tc-essential compounds	336
	18.3.2 Tc-tagged compounds	338
18.4	Peptide-Targeted Radiopharmaceuticals	343
18.5	Current Areas of Research	344
	18.5.1 Bioorganometallic chemistry	344
	18.5.2 Tc and solid supports	345
	18.5.3 Technetium-94m	349
18.6	Outlook	350
	References	352
19	⁴⁴Ru Perspectives of Ruthenium Complexes in Cancer Therapy	359
	<i>Olivier Lentzen, Cécile Moucheron and Andrée Kirsch-De Mesmaeker</i>	
19.1	Introduction	359
19.2	Ruthenium Complexes that Mimic Platinum Drugs	360
	19.2.1 Chloro-ammino derivatives	361
	19.2.2 Dimethyl-sulfoxide complexes	362
	19.2.3 Complexes with mixed chloride and heterocyclic ligands	364

19.3	Design of New Anti-cancer Compounds based on the Photoreactivity of Polyazaaromatic Ruthenium(II) Complexes	365
19.3.1	Energy transfer processes leading to photo-cleavages	367
19.3.2	Photoelectron transfer processes leading to DNA cleavages	368
19.3.3	Photoelectron transfer processes leading to photoadduct formation	371
19.4	Targeting Base Residues of Specific Sequences	373
19.5	Conclusions	375
	References	376
20	⁴⁵Rh Rhodium in Medicine	379
	<i>Florian P. Pruchnik</i>	
20.1	Introduction	379
20.2	Anti-tumor Activity of Rhodium Complexes	379
20.2.1	Rhodium(I) complexes	380
20.2.2	Rhodium(II) complexes	381
20.2.3	Rhodium(III) complexes	385
20.3	Anti-bacterial and Anti-parasitic Activity	388
20.4	Radiorhodium Agents	390
20.5	Photochemotherapy	391
20.6	Toxicity of Rhodium Complexes	392
	References	394
21	⁴⁶Pd The Use of Palladium Complexes in Medicine	399
	<i>Achilleas Garoufis, Sotiris K. Hadjikakou and Nick Hadjiliadis</i>	
21.1	Introduction	399

21.2	Anti-viral, Anti-fungal and Anti-microbial Activity of Pd(II) Complexes	400
21.2.1	Sulfur-donor ligands	400
21.2.2	Metal complexes of drugs used as ligands	404
21.2.3	Palladium(II) complexes with Schiff base ligands	405
21.2.4	Miscellaneous	406
21.3	Anti-tumor Activity of Pd(II) Complexes	407
21.3.1	Sulfur-donor ligands	407
21.3.2	Nitrogen and other donor atoms	410
21.4	Concluding Remarks	414
	References	415
22	⁵⁰Sn Tin Compounds and Their Therapeutic Potential	421
	<i>Marcel Gielen and Edward R.T. Tiekink</i>	
22.1	Introduction	421
22.2	Structures of Organotin Compounds in Solution	422
22.3	Anti-tumour Pre-screening	422
22.4	Early <i>In Vitro</i> Cytotoxicity Testing of Diorganotin Carboxylates	423
22.5	The Di-<i>n</i>-Butyltin Analogue of Carboplatin	425
22.6	Anti-tumour Potential of Triorganotin Carboxylates	426
22.7	Anti-tumour Screening of Organotin Derivatives of Biologically Relevant Substrates	427
22.8	Anti-tumour Potential of Fluorine-Substituted Organotin Carboxylates	428
22.9	Anti-tumour Potential of Boron-Containing Organotin Carboxylates	428

22.10	Anti-tumour Potential of Organotin Carboxylates-Containing Polyoxaalkyl Moieties	430
22.11	Mode of Action of Cytotoxic Organotin Compounds	431
22.12	Other Therapeutic Potential of Organotin Compounds	431
22.13	Therapeutic Potential of Tin Compounds Without Tin-to-Carbon Bonds	433
22.14	Conclusions	435
	Acknowledgements	435
	References	435
23	⁵¹Sb Antimony in Medicine	441
	<i>Siucheong Yan, Lan Jin and Hongzhe Sun</i>	
23.1	Introduction	441
23.2	The Chemistry of Antimony	441
23.3	Antimony in Medicine	443
	23.3.1 Historic view of antimony drugs	443
	23.3.2 Applications of antimony drugs as anti-leishmanial agents	444
	23.3.3 Other medicinal applications	445
23.4	Pharmacology, Toxicology and Metabolism of Antimony Drugs	447
	23.4.1 Pharmacology and human toxicology of antimony drugs	447
	23.4.2 Pharmacokinetics studies and clinical aspect of antimony drugs	448
23.5	Possible Mechanism of Action of Antimony Drugs: Interaction of Antimony with Biologically Relevant Molecules	449

23.5.1	General hypothesis on the mechanisms of action of antimony anti-leishmanial compounds	449
23.5.2	<i>In vitro</i> and <i>in vivo</i> reduction of antimony(V) drugs	449
23.5.3	Interaction of antimony(III) compounds with thiolate molecules	450
23.5.4	Inhibition of topoisomerase I from <i>Leishmania donovani</i> and formation of DNA-protein complexes by Sb ^V	453
23.5.5	Antimony-mediated DNA fragmentation, apoptosis and Ca ²⁺ -related programmed cell death in <i>Leishmania</i>	454
23.5.6	Interference of the exclusive purine scavenge pathway of <i>Leishmania</i>	454
23.5.7	Modulation and increase of cellular signaling of the host macrophage as a means of intracellular <i>Leishmania</i> elimination	455
23.6	Concluding Remarks	457
	Abbreviations	457
	Acknowledgement	457
	References	457
24	⁷⁵Re Therapeutic Rhenium Radiopharmaceuticals	463
	<i>Jonathan R. Dilworth and Paul S. Donnelly</i>	
24.1	Introduction	463
24.2	Synthetic Aspects of Rhenium Radiopharmaceuticals	466
	24.2.1 Complexes of bifunctional ligands	467
24.3	The Radiopharmaceutical Chemistry of Rhenium	467
	24.3.1 Complexes with oxo-cores	467
	24.3.2 Complexes with cores containing metal–nitrogen multiple bonds	472
	24.3.3 Complexes of the Re(I) tricarbonyl core	474

24.3.4	Organometallic approaches	479
24.3.5	Miscellaneous approaches	480
24.4	'First-Generation' Rhenium Agents	482
24.4.1	Bone-targeting phosphonate complexes	482
24.4.2	[Re(V)-oxo(DMSA)]	483
24.4.3	Rhenium agents for endovascular radiation therapy	484
24.4.4	Rhenium agents for radiation synovectomy	485
24.5	Summary	485
	References	486
25	⁷⁸Pt Platinum-Based Drugs	489
	<i>Viktor Brabec and Jana Kasparikova</i>	
25.1	Introduction, Anti-tumor Activity of Cisplatin	489
25.2	Anti-tumor Activity of Carboplatin, Oxaliplatin and Nedaplatin	490
25.3	Mechanism of Action of Cisplatin	491
25.4	Mechanism of Action of Carboplatin, Oxaliplatin and Nedaplatin	494
25.5	Activation of <i>trans</i> Geometry	495
25.6	Polynuclear Platinum Compounds	498
25.7	Platinum(IV) Compounds	499
25.8	Targeted Analogues	500
25.9	Anti-viral Activity	501
25.10	Combinations of Platinum Complexes with Other Agents	502
25.11	Conclusions	502
	Acknowledgements	503
	References	503

26	⁷⁹Au Gold-Based Metallotherapeutics: Use and Potential	507
	<i>Soo Yei Ho and Edward R.T. Tiekink</i>	
26.1	Preamble	507
26.2	The Physical and Chemical Properties of Gold	507
26.2.1	Physical properties of the element	507
26.2.2	Chemical reactivity of gold	508
26.2.3	Oxidation states and stereochemistries of gold complexes	508
26.3	Gold in Medicine	510
26.3.1	Historical perspective	510
26.3.2	Gold therapy for rheumatoid arthritis	511
26.4	Metabolism of Gold Drugs	514
26.4.1	Biological ligand exchange	514
26.4.2	Gold in cells: The thiol-shuttle model	514
26.4.3	Cyanide metabolites	515
26.5	Pharmacological Potential of Gold Complexes	516
26.5.1	Motivation for drug development	516
26.5.2	Anti-tumour properties of gold drugs	517
26.5.3	Tetrahedral gold(I) complexes	518
26.5.4	Auranofin analogues	518
26.5.5	Gold(III) complexes	520
26.6	Other Potential Clinical Applications of Au(I) Complexes	521
26.6.1	Anti-microbial activity	521
26.6.2	Anti-malaria activity	522
26.6.3	Treatment of bronchial asthma	523
26.6.4	Anti-HIV activity and AIDS	524
26.7	Conclusions and Outlook	524
	Acknowledgements	524
	References	524

27	^{83}Bi Bismuth-Based Pharmaceuticals	529
	<i>Neil Burford and Melanie D. Eelman</i>	
27.1	Introduction	529
27.2	Bismuth-Based Therapeutics	529
27.3	Fundamental Aspects of Bismuth Chemistry and Methods of Characterization	530
27.4	Hydroxycarboxylate Complexes of Bismuth	531
27.5	Development of Bioactive Bismuth Compounds	534
27.6	Interactions of Bismuth Compounds with Biological Molecules	537
27.7	Concluding Remarks	539
	References	539
28	Paramagnetic Metal Complexes as Contrast Agents for Magnetic Resonance Imaging	541
	<i>Silvio Aime, Alessandro Barge, Eliana Gianolio, Simonetta Geninatti Crich, Walter Dastrù and Fulvio Uggeri</i>	
28.1	Generalities on Magnetic Resonance Imaging (MRI) and Paramagnetic Contrast Agents	541
28.2	Determinants of the Relaxivity of Paramagnetic Metal Complexes	544
28.3	Responsive Agents	548
	28.3.1 pH sensitive agents	549
	28.3.2 Agents sensitive to the redox potential	551
	28.3.3 Enzyme responsive agents	552

- Zebrafish
 Li effects on, 5
- Zero charge point (zcp), 68–9
- Zifrosilone, 89, 90
- Zinc, 172, 400, 508
 acetate, 245
 anti-oxidant role, 246–7
 and cancer, 245–51
 prostate, 249–51, 250
 catalytic, structural and regulatory
 functions, 237–8
 and common cold, 245
 deficiency, 238–40
 dietary factors in, 241
 and DNA damage, 246
 and oxidative stress, 246–7
 risk factors for, 241–2
 side effects, 239
 and DNA repair, 247–9
 drug interactions, 252
 gluconate, 245, 252
 and growth retardation, 239–40
 high-dose, 243
 intake recommendations, 241–2
 intranasal, 245, 251–2
 as a metallothepapeutic agent,
 237–57
 oxide, 251
 safety, 251–2
 sulfate, 243, 251
 sulfide, 259, 279
 and susceptibility to disease,
 240
 therapeutic uses, 243–4
 toxicity, 251–2
- Zirconium oxide, 66

Index compiled by L.N. Derrick




Plate 1 (Figure 2.1) The mechanism of boron neutron capture therapy (BNCT)




Plate 2 (Figure 19.12) The $[\text{Ru}^{\text{II}}(\text{TAP})_2\text{dip}']^{2+}$ complex anchored onto a synthetic oligonucleotide at the level of the 5 position of a thymine




(a)




(b)

Plate 3 (Figure 23.1) X-ray crystal structures of antimony(III) citrate (a) and potassium antimony(III) tartrate (PAT, $K_2Sb_2(C_4H_2O_6)_2$) (b)



(a)



(b)

Plate 4 (Figure 23.4) Structures of $Sb(T(S)_2)$ complex together with the oxidized form of trypanothione (adapted with permission from Ref. 90)